MedTrace Logo

Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

NCT06500299 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-07-15

No results posted yet for this study

Summary

It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.

Conditions

  • Overweight and Obesity

Interventions

DRUG

HDM1002 100 mg QD

HDM1002 tablets 100mg daily, 12weeks

DRUG

HDM1002 200 mg QD 12weeks

HDM1002 tablets 200mg daily, 12weeks

DRUG

HDM1002 400 mg QD 12weeks

HDM1002 tablets 400mg daily, 12weeks

DRUG

Placebo

Matching placebo will be provided

Sponsors & Collaborators

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaoying Li · Zhongshan Hospital, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-15
Primary Completion
2024-10-30
Completion
2024-11-30
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06500299 on ClinicalTrials.gov